NCT07168356View on ClinicalTrials.gov

A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease

PHASE1RecruitingINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

September 16, 2025

Primary Completion Date

April 28, 2026

Study Completion Date

August 18, 2026

Conditions

Hepatitis B

Interventions

DRUG

Bepirovirsen

Bepirovirsen will be administered.

Trial Locations (1)

33603

RECRUITING

GSK Investigational Site, Tampa

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY